Literature DB >> 7743510

Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach.

M J Blaser1, G I Perez-Perez, H Kleanthous, T L Cover, R M Peek, P H Chyou, G N Stemmermann, A Nomura.   

Abstract

To determine whether infection with a Helicobacter pylori strain possessing cagA is associated with an increased risk of development of adenocarcinoma of the stomach, we used a nested case-control study based on a cohort of 5443 Japanese-American men in Oahu, Hawaii, who had a physical examination and a phlebotomy during 1967 to 1970. We matched 103 H. pylori-infected men who developed gastric cancer during a 21-year surveillence period with 103 H. pylori-infected men who did not develop gastric cancer and tested stored serum specimens from patients and controls for the presence of serum IgG to the cagA product of H. pylori using an ELISA. The serum IgG assay using a recombinant CagA fragment had a sensitivity of 94.4% and a specificity of 92.5% when used in a clinically defined population; serological results were stable for more than 7 years. For men with antibodies to CagA, the odds ratio of developing gastric cancer was 1.9 (95% confidence interval, 0.9-4.0); for intestinal type cancer of the distal stomach, the odds ratio was 2.3 (95% confidence interval, 1.0-5.2). Age < 72 years and advanced tumor stage at diagnosis were significantly associated with CagA seropositivity. We conclude that infection with a cagA-positive H. pylori strain in comparison with a cagA-negative strain somewhat increases the risk for development of gastric cancer, especially intestinal type affecting the distal stomach.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7743510

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  592 in total

1.  Analysis of Helicobacter pylori vacA gene and serum antibodies to VacA in Japan.

Authors:  D Shirasaka; N Aoyama; K Satonaka; K Shirakawa; H Yoshida; T Sakai; T Ikemura; Y Shinoda; M Sakashita; M Miyamoto; K Yahiro; A Wada; H Kurazono; T Hirayama; M Kasuga
Journal:  Dig Dis Sci       Date:  2000-04       Impact factor: 3.199

2.  Modulation of Helicobacter pylori induced interleukin-8 synthesis in gastric epithelial cells mediated by cag PAI encoded VirD4 homologue.

Authors:  J E Crabtree; D Kersulyte; S D Li; I J Lindley; D E Berg
Journal:  J Clin Pathol       Date:  1999-09       Impact factor: 3.411

3.  Bacterial polymorphisms and disease in humans.

Authors:  M J Blaser; J M Musser
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

4.  CagA: a role at last.

Authors:  J C Atherton
Journal:  Gut       Date:  2000-09       Impact factor: 23.059

5.  Expression of the CagA gene ofH. pylori and application of its product.

Authors:  Feng-Chan Han; Xiao-Jun Yan; Cheng-Zhi Su
Journal:  World J Gastroenterol       Date:  2000-02       Impact factor: 5.742

6.  Association between Helicobacter pylori and gastric cancer: current knowledge and future research.

Authors:  Harry Hua-Xiang Xia
Journal:  World J Gastroenterol       Date:  1998-04-15       Impact factor: 5.742

7.  Clinical relevance of the babA2 genotype of Helicobacter pylori in Japanese clinical isolates.

Authors:  T Mizushima; T Sugiyama; Y Komatsu; J Ishizuka; M Kato; M Asaka
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

8.  The phenotype of gastric mucosa coexisting with Barrett's oesophagus.

Authors:  M Rugge; V Russo; G Busatto; R M Genta; F Di Mario; F Farinati; D Y Graham
Journal:  J Clin Pathol       Date:  2001-06       Impact factor: 3.411

9.  Phenotypic and genotypic variation in methylases involved in type II restriction-modification systems in Helicobacter pylori.

Authors:  Tohru Takata; Rahul Aras; Donald Tavakoli; Takafumi Ando; Asalia Z Olivares; Martin J Blaser
Journal:  Nucleic Acids Res       Date:  2002-06-01       Impact factor: 16.971

10.  Role of a Stem-Loop Structure in Helicobacter pylori cagA Transcript Stability.

Authors:  John T Loh; Aung Soe Lin; Amber C Beckett; Mark S McClain; Timothy L Cover
Journal:  Infect Immun       Date:  2019-01-24       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.